Our characterization of CRL4/BIRC3 axis provides new insights into mechanisms underlying ovarian cancer chemoresistance, and CRL4 may serve as a potential and novel therapeutic target for overcoming the bottle neck of ovarian cancer chemoresistance. This evidence concerns the gene BIRC3 and ovarian carcinoma.